GPCR drug discovery: new agents, targets and indications

Area of Science:

• Pharmacology
• Drug Discovery
• Biochemistry

Background:

• G protein-coupled receptors (GPCRs) represent a major class of drug targets due to their critical roles in various physiological and pathological processes.
• The GPCR superfamily is extensively targeted by approved medications and agents under clinical investigation.

Purpose of the Study:

• To analyze current trends in drug discovery and development for the GPCR superfamily.
• To provide a comprehensive overview of approved GPCR-targeting drugs, clinical trial candidates, and emerging therapeutic areas.

Main Methods:

• Systematic review of regulatory-approved drugs and clinical trial data for GPCR-targeting agents.
• Analysis of drug targets, indications, sales data, and clinical trial progression.
• Identification of novel targets and emerging modalities such as allosteric modulators and biologics.

Main Results:

• 516 drugs targeting 121 GPCRs are approved, constituting 36% of all approved drugs.
• 337 agents targeting 133 GPCRs, including 30 novel targets, are in clinical trials.
• Significant growth in GPCR drug development for metabolic diseases, oncology, and immunology, with substantial market value in diabetes and obesity treatments.

Conclusions:

• GPCRs remain a highly productive area for drug discovery, with a vast number of approved and investigational agents.
• Emerging trends include a focus on novel targets, allosteric modulators, biologics, and expanding applications in metabolic diseases, oncology, and immunology.
• Untapped target-disease associations and pathway-biased signaling offer future opportunities for GPCR drug development.